Axovant is accelerating the development of innovative gene therapy products that address serious neurological and neuromuscular diseases with significant unmet medical needs. We are currently studying gene therapy candidates for GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases, and Parkinsonâs disease in clinical trials and are working quickly to bring gene therapy candidates for other indications to patients in the clinic. We know that patients canât wait, so neither will we. Source
No articles found.
Gulf Chronic Care, Inc. was established specifically to address the diabetic epide...
Gulf Chronic Care, Inc. was established specifi...
MTBC is a healthcare information technology company that provides a fully integrat...
MTBC is a healthcare information technology com...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
Emisphere Technologies is a Drug Delivery Company whose core business strategy is ...
Emisphere Technologies is a Drug Delivery Compa...
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...
Neurotrope is a clinical-stage biotech company ...
Mustang Bio, Inc. (âMustangâ), a Fortress Biotech Company, is a clinical-stage...
Mustang Bio, Inc. (âMustangâ), a Fortress B...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
Adamas Pharmaceuticals, Inc. is using its deep understanding of time-dependent bio...
Adamas Pharmaceuticals, Inc. is using its deep ...
Join the National Investor Network and get the latest information with your interests in mind.